Close Menu

At MIT's Tech Review, Emily Singer discusses new genetic tests launched by Decode this week. One looks for variations linked to various cardiovascular diseases and the other for variations associated with cancer risk and they are priced at $195 and $225. However, the clinical utility of tests that include multiple genetic risk factors hasn't yet been worked out. "We don't yet know how to combine such data in an accurate way," UNC-Chapel Hill's James Evans says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.